In a nutshell The study aimed to investigate the frequency and severity of skin rash-like symptoms known as exanthema and its relationship with treatment outcome with vemurafenib (Zelboraf) alone or vemurafenib combined with cobimetinib (Cotellic) in patients with advanced melanoma. The study showed that the appearance of exanthema within 6 weeks of...
Read More
In a nutshell The study evaluated whether the combination of atezolizumab (Tecentriq), vemurafenib (Zelboraf), and cobimetinib (Cotellic) or AVC can effectively treat patients with BRAFV600 mutation-positive advanced melanoma (AM). The authors found that this combination was safe and effective as an initial treatment in such...
Read More
In a nutshell This study wanted to find out how well patients with advanced melanoma treated with certain medications survived outside of clinical trials. The study found that patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) or patients treated with anti-PD1 antibodies had longer survival compared to those treated with BRAF/MEK...
Read More
In a nutshell This study investigated atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) in BRAF-mutated melanoma. They found that this combination is promising and well tolerated in these patients. Some background Melanoma or skin cancer is often by...
Read More
In a nutshell This study investigated the effect of combined dabrafenib (Tafinlar), trametinib (Mekinist) and pembrolizumab (Keytruda) in melanoma. They found that this combination improved survival in advanced melanoma. Some background Melanoma or skin cancer is a common cancer. Genetic mutations can lead to...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors. The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states. The details Relapsed/refractory...
Read More
In a nutshell This study investigated the effect of dabrafenib (Tafinlar and trametinib (Mekinist) on patient-reported outcomes (PROs) in melanoma. They found that this treatment combination did not effect PROs. Some background Melanoma is a type of skin cancer. The prognosis for melanoma has improved in recent years. Targeted therapies...
Read MoreIn a nutshell This trial aims to investigate the effects of the anti-cancer drugs dabrafenib (Taflinlar) and trametinib (Mekinist) on fever related side effects when treating patients with advanced melanoma that has been surgically removed. The main outcome that will be measured is the rate of fever and raised body temperature. The details High body...
Read More
In a nutshell This study wanted to find out which combination of medication is better for treatment of advanced melanoma, paclitaxel (Taxol), paclitaxel plus trametinib (Mekinist), or paclitaxel plus pazopanib (Votrient). The study found that paclitaxel and trametinib had the best response, but had a lot of side effects, and there was no effect on...
Read More
In a nutshell This study wanted to see how long patients with melanoma would take to relapse (stop responding) when treated with dabrafenib (Tafinlar) plus tramentinib (Mekinst) after surgery. The study found that after four-years, the relapse rate was 59% compared to 40% in those who did not use the medications after surgery. Some background A...
Read More
In a nutshell This study wanted to see if using a different BRAF inhibitor was effective in the treatment of patients with melanoma. The study found that retreating with a slightly different BRAF inhibitor worked well. Some background Around 50% of patients with melanoma that has spread have a mutation in one of their genes. This gene is...
Read More
In a nutshell This study wanted to find out which treatment for melanoma cancer worked better, encorafenib (Braftovi) + binimetinib (Mektovi), encorafenib alone, or vemurafenib (Zelboraf) alone. The study found that encorafenib + binimetinib worked well and was safe, compared to vemurafenib and encorafenib. Some background In about 50% of patients...
Read More
